References
- Armarnik S, Sheiner E, Piura B, et al. Obstetric outcome following cervical conization. Arch Gynecol Obstet 2011;283(4):765-9
- Anorlu RI. Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters 2008;16(32):41-9
- Vici P, Mariani L, Pizzuti L, et al. Emerging biological treatments for uterine cervical carcinoma. J Cancer 2014;5(2):86-97
- Bernard HU. Established and potential strategies against papillomavirus infections. J Antimicrob Chemother 2004;53(2):137-9
- Hampson L, Kitchener HC, Hampson IN. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther 2006;11(6):813-25
- Batman G, OLiver AW, Zehbe I, et al. Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-postive cervical carcinoma cells. Antivir Ther 2011;16(4):515-25
- Zehbe I, Richard C, Lee KF, et al. Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions. Antiviral Res 2011;91(2):161-6
- Barillari G, Iovane A, Bacigalupo I, et al. Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. Aids 2012;26(8):909-19
- Bernstein WB, Dennis PA. Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS 2008;3(6):666-75
- Andre P, Groettrup M, Klenerman P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998;95(22):13120-4
- Ahluwalia MS, Patton C, Stevens G, et al. Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas. J Neurooncol 2012;102(2):317-21
- Gantt S, Casper C, Ambinder RF. Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Curr Opin Oncol 2013;25(5):495-502
- Hoover AC, Milhem MM, Anderson CM, et al. Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial. Head Neck 2014. [Epub ahead of print]
- Pearson J. Safety study of nelfinavir + cisplatin + pelvic radiation therapy to treat cervical cancer. US National Inst of Health. 2014. Available from: http://clinicaltrials.gov/show/NCT01485731
- Firnhaber C, Westreich D, Schulze D, et al. Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa. J Int AIDS Soc 2012;15(2):17382
- Paramsothy P, Jamieson DJ, Heilig CM, et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009;113(1):26-31
- Lucci J. A phase II single-arm intervention trial of nelfinavir in patients with grade 2/3 or 3 cervical intraepithelial neoplasia. Available from: http://clinicaltrials.gov/show/NCT01925378
- Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003;95(17):1336-43
- Batman G, Hampson L, Hampson IN. Lessons from repurposing HIV drugs: a prospective novel strategy for drug design. Future Virology 2011;6(9):1021-3
- Piccinini M, Rinaudo MT, Anselmino A, et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir Ther 2005;10(2):215-23